Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 1 |
Top 5 Target | Count |
---|---|
PDL1(Programmed death-ligand 1) | 1 |
Target |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NLRP3 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date16 Oct 2024 |
Sponsor / Collaborator |
Start Date01 Oct 2024 |
Sponsor / Collaborator |
Start Date09 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CN116617365 ( PDL1 ) | Pharyngeal Diseases More | Discovery |
DNAzyme targeting EBV-LMP1(Xiangya Hospital of Central South University) | Nasopharyngeal Carcinoma More | Pending |
SI-2 ( NLRP3 ) | Inflammation More | Pending |